Becton Dickinson & Co (MIL:1BDX)
€ 211.5 -2.1 (-0.98%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.37 PB Ratio: 2.48 GF Score: 64/100

Becton Dickinson and Co at Bank of America Healthcare Conference Transcript

May 11, 2022 / 07:00PM GMT
Travis Lee Steed
BofA Securities, Research Division - MD

Welcome to the BofA Healthcare Conference. Up next, we have Becton, Dickinson. I'm Travis Steed, the medical device analyst here at BofA, and we're welcome to have Chris DelOrefice, Chief Financial Officer; and Simon Campion, President of the Interventional segment. So great. Welcome. And Chris, I think you wanted to start off with some opening comments, kind of just a few takeaway, some -- the recent quarter that you had last week.

Christopher DelOrefice
Becton, Dickinson and Company - Executive VP & CFO

Yes. Absolutely. So first thing, thanks for having us. Thanks, everyone, for joining. Good to see everyone in person.

Yes, as I reflect on the quarter, I think a couple of things. One -- I think 2 key things maybe to highlight. One, I think what you're really seeing play out in both our second fiscal quarter and our first quarter results is really our BD 2025 strategy coming to life, really strong growth. As you saw, as a matter of fact, year-to-date, we're just about 9% growth. And I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot